How I treat HIV-associated multicentric Castleman disease

Bower, Mark

doi:10.1182/blood-2010-07-290213

Cited by 119 publications

(100 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 While standardized treatment modalities have not yet been established, several promising approaches are being pursued. 16,24,25 Antineoplastic chemotherapy with single or combination agents has yielded clinical remissions, though the responses are typically transient and drug toxicities limit extended use. Successes have been reported with immunotherapy using monoclonal antibodies (mAbs) tocilizumab (Actemra ® ), 26 and siltuximab 27 against interlekin-6 or rituximab against the B-cell antigen CD20, 18,[28][29][30][31] though the latter agent has been complicated by aggravation of KS lesions.…”

Section: Resultsmentioning

confidence: 99%

Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein

Chatterjee

Chandran

Berger

2012

mAbs

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein

Chatterjee

Chandran

Berger

2012

mAbs

View full text Add to dashboard Cite

“…The natural history of MCD is variable. Some patients may present with indolent disease and very slow progression over months to years, while others experience a relapsing-remitting course or an acute and fulminant disease that can be fatal within weeks; the latter courses are more common in pa-tients with HIV associated MCD 7,8 .…”

Section: Discussionmentioning

confidence: 99%

Multicentric Castleman's Disease in a 21 Years Old Female : A Rare But Important Condition

Chowdhury

Reshma

Islam

2017

Chatt Maa Shi Hosp Med Coll J

View full text Add to dashboard Cite

Castleman's disease, also known as angiofollicular lymph node hyperplasia, is a rare disease with two known expansion types, unicentric and multicentric, which plays a major role in determining therapy. The rare multicentric type is a lymphoproliferative disorder of unknown etiology and is characterized by various clinical manifestations and multiple organ involvement. This disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established till now. We here report a case of rare Multicentric Castleman's Disease (MCD) in a 21yrs old female. She presented with slowly enlarging lymph nodes in cervical and inguinal regions which lead to a histological diagnosis of this rare condition. Its clinical features, types, relevant investigations and current treatment modalities are discussed. Though rare, early suspicion of this condition may relieve the suffering, avoid unnecessary investigations, give opportunity to choose treatment options and can save lives.

show abstract

“…The anti-CD20 monoclonal antibody rituximab yields good response, especially when used with chemotherapy, but showed to worsen Kaposi sarcoma when used in HIV-positive patients with high viral load [9,10].…”

Section: Discussionmentioning

confidence: 99%

Unicentric Retroperitoneal Castleman Disease Presenting with Pleural Effusion

Aa¹,

Alaqqad²,

Alqasem³

et al. 2017

Anat Physiol

View full text Add to dashboard Cite

Castleman disease (Angiofollicular Lymph Node Hyperplasia AFH) is a rare lymphoproliferative disorder that is especially uncommon in the retroperitoneal area. We report a case of 32 year old male who was complaining of shortness of breath and was found to have right sided pleural effusion. Further investigations revealed right sided retroperitoneal mass which was completely excised laparoscopically. Pathologic diagnosis came out as Castleman disease. The patient recovered well after surgery and his shortness of breath and pleural effusion did not recur for the subsequent 6 months of follow up.

show abstract

How I treat HIV-associated multicentric Castleman disease

Cited by 119 publications

References 66 publications

Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein

Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein

Multicentric Castleman's Disease in a 21 Years Old Female : A Rare But Important Condition

Unicentric Retroperitoneal Castleman Disease Presenting with Pleural Effusion

Contact Info

Product

Resources

About